A Phase 1 trial of KTX 201 for Solid tumours and Haematological malignancies
Latest Information Update: 05 Mar 2021
At a glance
- Drugs KTX 201 (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Adverse reactions
- Sponsors Kymera Therapeutics
- 05 Mar 2021 New trial record
- 02 Mar 2021 According to a Kymera Therapeutics media release, this study is expected to begin in 2021.